| Literature DB >> 35883489 |
Chiara Abate1, Federica Carnamucio1, Ottavia Giuffrè1, Claudia Foti1.
Abstract
In recent years, the study of metal complexes and metal-based nanomaterials has aroused particular interest, leading to the promotion of new effective systems for the abatement of various viral diseases. Starting from the analysis of chemical properties, this review focuses on the employment of metal-based nanoparticles as antiviral drugs and how this interaction leads to a substantial enhancement in antiviral activity. The use of metal-based antiviral drugs has also spread for the formulation of antiviral vaccines, thanks especially to the remarkable adjuvant activities of some of the metal complexes. In particular, the small size and inert nature of Au- and Ag-based nanoparticles have been exploited for the design of systems for antiviral drug delivery, leading to the development of specific and safe therapies that lead to a decrease in side effects.Entities:
Keywords: antiviral drugs; drug delivery; metal compounds; metal nanoparticles; vaccines
Mesh:
Substances:
Year: 2022 PMID: 35883489 PMCID: PMC9312833 DOI: 10.3390/biom12070933
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Schematic representation of the main properties and applications of metal-based compounds.
Metal complexes and their applications in antiviral therapy.
| Metal | Ligand | Application | Virus | Ref. |
|---|---|---|---|---|
| Au(I) | 2,3,4,6-tetra-o-acetyl-L-thio-β-D-glycol-pyranoses-S-(triethyl-phosphine) (AF) | Antiviral therapy | HIV-1, SARS-CoV-2 | [ |
| Aurothiomalate | Antiviral therapy | HIV-1 | [ | |
| Aurothioglucose | Antiviral therapy | HIV-1 | [ | |
| Ga(III) | Curcumin | Antiviral therapy | HSV-1 | [ |
| Co(III) | Doxovir | Antiviral therapy | HSV-1 | [ |
| Cu(II) Ni(II) Co(II) Zn(II) Cr(III) | Tenoxicam, valine | Vaccine therapy | Infectious Bovine Rhinotracheitis (IBR) | [ |
| 5,5-[3-diyl)]bis(quinolin-8-ole) | Vaccine therapy | Bovine respiratory syncytial (BRS) | [ | |
| AuNPs | FMD virus-like particles (VLPs) | Vaccine therapy | Foot-and-mouth disease (FMD) | [ |
| West Nile Virus (WNV) envelope (E) protein | Vaccine therapy | West Nile Virus (WNV) | [ | |
| STG antigen | Vaccine therapy | Enteropathogenic coronavirus of transmissible porcine gastroenteritis (STG) | [ | |
| PEG-S461-493 | Vaccine therapy | SARS-CoV-2 | [ | |
| Protein S | Vaccine therapy | SARS-CoV-2 | [ | |
| Raltegravir (RAL) | Drug delivery system | HIV | [ | |
| FMD virus protein | Drug delivery system | FMD | [ | |
| Stavudine | Drug delivery system | HIV | [ | |
| siRNA | Drug delivery system | DENV | [ | |
| Fe(III) | NanoMOFs | Drug delivery system | HIV | [ |
| Tenoxicam, valine | Vaccine therapy | IBR | [ | |
| NiNPs | His-Tat cationic antigen | Drug delivery system | HIV | [ |
| AgNPs | Spike proteins | Drug delivery system | SARS-CoV-2 | [ |